LianBio Cleared to Start China Phase II Trial of FGFR Inhibitor

LianBio, a Shanghai-Princeton company, is approved to start a China Phase IIa trial of an FGFR inhibitor, infigratinib. Infigratinib will be tested in patients who have advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification. LianBio acquired Greater China rights to infigratinib from QED Therapeutics, a subsidiary of BridgeBio, in a $532 million deal announced in August. The news came as BridgeBio filed a US NDA for infigratinib as a second-line cholangiocarcinoma treatment. More details.... Stock Symbol: (NSDQ: BBIO) Share this with colleagues: // //